lopinavir has been researched along with Adverse Drug Event in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (13.04) | 29.6817 |
| 2010's | 13 (56.52) | 24.3611 |
| 2020's | 7 (30.43) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Cevenini, F; Fallani, E; Lazzerini, PE; Saponara, S; Verdini, A | 1 |
| Bhardwaj, M; Chiu, MN; Sah, SP | 1 |
| Dai, L; Li, J; Liu, A; Mahajan, SD; Schwartz, SA; Scott, SR; Shao, Y; Su, B; Sun, L; Wu, H; Ye, J; Yu, H; Zhang, H; Zhang, T | 1 |
| Hong, D; Hu, X; Li, L; Ni, J; Shan, W; Yang, H; Zhang, X; Zhao, Q | 1 |
| Grundmark, B; Vidlin, SH; Watson, S; Zekarias, A | 1 |
| Battegay, M; Leuppi-Taegtmeyer, A; Marzolini, C; Sendi, P; Stader, F; Stoeckle, M | 1 |
| Aweeka, F; Bradford, S; Browning, R; Coletti, A; Costello, D; Graham, B; Hughes, E; Kamthunzi, P; Kawalazira, R; Mmbaga, BT; Moye, J; Musoke, P; Nathoo, K; Norman, J; Owor, M; Purdue, L; Reding, C; Tierney, C; Whalen, ME; Wiesner, L; Ziemba, L | 1 |
| Bonnabry, P; Eggimann, F; Grauser, D; Grosgurin, O; Guignard, B; Reny, JL; Samer, C; Skalafouris, C; Stirnemann, J | 1 |
| Abongomera, G; Easterbrook, P; Hakim, JG; Hoppe, A; Kambugu, A; Kityo, C; Lugemwa, A; Mugyenyi, P; Mwebaze, R; Mweemba, A; Paton, NI; Siika, A; Thomason, MJ; Thompson, J; van Oosterhout, JJ; Walker, AS | 1 |
| Brites, C; Lorenzo, C; Luz, E; Netto, EM; Nóbrega, I; Travassos, AG | 1 |
| Eom, JS; Joo, YS; Jung, Y; Ko, JH; Lee, JS; Park, SY; Peck, KR; Shi, H; Son, JS; Woo, HJ | 1 |
| Akanmu, S; Brown, B; Chang, C; Darin, KM; David, N; Kanki, PJ; Ogunbosi, B; Okonkwo, P; Oladokun, R; Olaitan, O; Rawizza, HE; Scarsi, KK | 1 |
| Arathoon, E; Baraldi, E; Lavreys, L; Lim, PL; Opravil, M; Schneider, S; Van De Casteele, T | 1 |
| Achan, J; Charlebois, E; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, M; Mwangwa, F; Rosenthal, PJ; Ruel, TD | 1 |
| Crespo, M; Curran, A; Domingo, P; Fernández, I; Imaz, A; Iribarren, JA; Knobel, H; Martínez, E; Monteiro, P; Peñaranda, M; Podzamczer, D; Villar, J | 1 |
| Berrio-Galan, D; Bravo, I; Clotet, B; Llibre, JM; Miranda, C; Moltó, J; Paredes, R; Pérez-Alvarez, N; Pérez-Alvarez, S; Santos, JR | 1 |
| Beukel van den Bout-van den, CJ; Bosch, ME; Burger, DM; Koopmans, PP; van der Ven, AJ | 1 |
| Escobar Rodríguez, I; Esteban Alba, C | 1 |
| Baran, R; Dietz, B; Hornberger, J; Podsadecki, T; Shewade, A; Simpson, K | 1 |
| Absalon, J; Johnson, M; McGrath, D; Sheppard, L; Squires, KE; Uy, J; Yang, R | 1 |
| Ackad, N; Andrade-Villanueva, J; Bortolozzi, R; Cahn, P; Casiró, AD; Cassetti, I; Junod, P; Krolewiecki, A; Longo, N; Lupo, SH; Montaner, J; Patterson, P; Rampakakis, E; Sampalis, JS; Sierra-Madero, J | 1 |
3 review(s) available for lopinavir and Adverse Drug Event
| Article | Year |
|---|---|
Safety profile of COVID-19 drugs in a real clinical setting.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Reproducibility of Results; Ritonavir; SARS-CoV-2 | 2022 |
[Pharmacoeconomic aspects of lopinavir/ritonavir monotherapy].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Cost Control; Cost-Benefit Analysis; Direct Service Costs; Drug Combinations; Drug Costs; Drug-Related Side Effects and Adverse Reactions; European Union; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Prescription Fees; Pyrimidinones; Ritonavir; Treatment Outcome | 2008 |
Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy.
Topics: Drug Administration Schedule; Drug Combinations; Drug Synergism; Drug-Related Side Effects and Adverse Reactions; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Practice Guidelines as Topic; Pyrimidinones; Ritonavir | 2010 |
7 trial(s) available for lopinavir and Adverse Drug Event
| Article | Year |
|---|---|
Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092.
Topics: Africa South of the Sahara; Anti-HIV Agents; Area Under Curve; Child, Preschool; Chromatography, Liquid; Cohort Studies; Drug Combinations; Drug Elimination Routes; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Lamivudine; Lopinavir; Male; Patient Safety; Ritonavir; Severe Acute Malnutrition; Tandem Mass Spectrometry; Zidovudine | 2021 |
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
Topics: Adolescent; Adult; Africa South of the Sahara; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2018 |
Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant women.
Topics: Adolescent; Adult; Anti-HIV Agents; Brazil; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Pilot Projects; Pregnancy; Pregnancy Complications, Infectious; Raltegravir Potassium; Ritonavir; RNA, Viral; Sustained Virologic Response; Treatment Outcome; Viral Load; Young Adult | 2018 |
Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2013 |
Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Lopinavir; Malaria; Male; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome; Uganda; Viral Load | 2014 |
Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Sex Factors | 2011 |
Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pilot Projects; Precision Medicine; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Young Adult | 2011 |
13 other study(ies) available for lopinavir and Adverse Drug Event
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Off-Label Use of Hydroxychloroquine in COVID-19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance.
Topics: Azithromycin; COVID-19 Drug Treatment; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Off-Label Use; Pharmacovigilance; Ritonavir | 2022 |
Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Asian People; Beijing; Benzoxazines; Case-Control Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Dyslipidemias; Female; HIV Infections; Hospitals, University; Humans; Lipids; Lopinavir; Male; Middle Aged; Retrospective Studies; Ritonavir; Treatment Outcome | 2019 |
[Establishment of a rapid identification of adverse drug reaction program in R language implementation based on monitoring data].
Topics: Databases, Pharmaceutical; Decision Making, Computer-Assisted; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; HIV Protease Inhibitors; Humans; Liver; Lopinavir; Models, Statistical; Reproducibility of Results; Software | 2020 |
Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
Topics: Abdominal Pain; Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Chemical and Drug Induced Liver Injury; Chloroquine; COVID-19 Drug Treatment; Databases, Pharmaceutical; Diarrhea; Drug Combinations; Drug Eruptions; Drug Repositioning; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Male; Nausea; Oseltamivir; Ritonavir; Sex Distribution; Sex Factors; Vomiting | 2020 |
Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19.
Topics: COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Long QT Syndrome; Lopinavir; Male; Pharmaceutical Preparations; SARS-CoV-2; Sex Characteristics | 2021 |
Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19.
Topics: COVID-19; COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lopinavir; Ritonavir; SARS-CoV-2 | 2023 |
Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers.
Topics: Adult; Aged; Antiviral Agents; Coronavirus Infections; Drug-Related Side Effects and Adverse Reactions; Female; Health Personnel; Humans; Incidence; Lopinavir; Male; Post-Exposure Prophylaxis; Retrospective Studies; Ribavirin; Ritonavir; Young Adult | 2019 |
Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART.
Topics: Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Biomarkers; Coinfection; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Lopinavir; Male; Retrospective Studies; Rifabutin; Ritonavir; Treatment Outcome; Tuberculosis | 2019 |
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Maintenance Chemotherapy; Male; Middle Aged; Retrospective Studies; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2014 |
Monotherapy with boosted PIs as an ART simplification strategy in clinical practice.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Retrospective Studies; Ritonavir; Sulfonamides; Survival Analysis; Treatment Outcome; Viral Load | 2015 |
Toxic lopinavir concentrations in an HIV-1 infected patient taking herbal medications.
Topics: Diarrhea; Drug-Related Side Effects and Adverse Reactions; Herb-Drug Interactions; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones | 2008 |